AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Translation factor GUF1, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8N442

UPID:

GUF1_HUMAN

Alternative names:

Elongation factor 4 homolog; GTPase GUF1; Ribosomal back-translocase

Alternative UPACC:

Q8N442; Q5XKM8; Q9H710; Q9H8U4

Background:

Translation factor GUF1, mitochondrial, also known as Elongation factor 4 homolog, GTPase GUF1, and Ribosomal back-translocase, plays a pivotal role in mitochondrial protein synthesis. It ensures the accuracy of protein translation by facilitating a one-codon backward translocation of tRNAs on ribosomes that have translocated improperly, binding to mitochondrial ribosomes in a GTP-dependent manner.

Therapeutic significance:

Linked to Developmental and epileptic encephalopathy 40 (DEE40), a severe early-onset epilepsy with neurodevelopmental impairment, the study of Translation factor GUF1, mitochondrial, offers a promising avenue for therapeutic intervention. Understanding its function could lead to novel strategies for managing DEE40, improving prognosis and quality of life for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.